Clinical trials: Breast Cancer/ Metastatic Breast Cancer
Breast Cancer
Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of liposomal doxorubicin is more effective for metastatic breast cancer.
- Trial name
- NCT00005980
- Testing
- pegylated liposomal doxorubicin hydrochloride
- Where
- 14 sites in Austria, France and 7 more
- Volunteers
- 116 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Neoplasms
A Study of Local Therapy for the Treatment of Brain Metastases From HER2 Positive Breast Cancer
This study aims to show that brain metastases from Human Epidermal Growth Factor Receptor Type 2 (HER2) positive breast cancers are able to be controlled by local therapies, Stereotactic Radiosurgery (SRS) and/or Neurosurgery…
- Trial name
- Local HER-O (NCT02898727)
- Testing
- Local Therapy
- Where
- Australia
- Volunteers
- 25 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Breast Cancer, Neoplasm Metastasis
Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer
This is an open phase II study evaluating the efficacy and safety of the non pegylated liposomal doxorubicin (Myocet®), trastuzumab (Herceptin®), and docetaxel (Taxotere®) combination as first-line treatment of patients with…
- Trial name
- MYOHERTAX (NCT00377780)
- Testing
- Non pegylated liposomal doxorubicin, trastuzumab, docetaxel
- Where
- 7 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- Laurence J.C. van Warmerdam
Breast Cancer
Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop tumor cells from dividing so they…
- Trial name
- NCT00075673
- Testing
- celecoxib, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study
This disease registry is a prospective, multicenter non-interventional study designed to observe the different anticancer treatment regimens and their sequencing throughout the course of the disease in participants with…
- Trial name
- ESTHER (NCT02393924)
- Testing
- No intervention
- Where
- 30 sites in United Kingdom
- Volunteers
- 311 people
- Sponsor
- Hoffmann-La Roche
Neoplasm Metastasis, Lung Neoplasms
Proton MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response.
The aim of the study is to investigate the feasibility of in vivo single volume MR spectroscopy in evaluation of treatment response in patients with brain metastases, using 3T MR instrument.
- Conditions
- Neoplasm Metastasis, Lung Neoplasms, Breast Neoplasms, Melanoma
- Trial name
- NCT00184288
- Where
- Norway
- Sponsor
- Norwegian University of Science and Technology
Cancer, Breast Cancer
Genomic Investigation of Unusual Responders
Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic…
- Conditions
- Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- GENIUS (NCT03740503)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Metastatic Breast Cancer
A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer
To evaluate efficacy and toxicity of doxorubicin/Genexol-PM in metastatic breast cancer 1. Primary Purpose: response rate 2. Secondary purpose: toxicity, progression-free survival, overall survival
- Trial name
- NCT01784120
- Testing
- Doxorubicin/Genexol-PM
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Gachon University Gil Medical Center
Spinal Tumor
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
The goal of the first part of this clinical research study is to learn how to deliver more accurate radiation treatment of tumors in the spine.
- Trial name
- NCT01624220
- Testing
- Spinal SBRT (Standard Dose), Spinal SBRT (Higher Dose), Gold Seed Implantation
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Metastases, Adult
Neoadjuvant Immunotherapy in Brain Metastases
The purpose of this phase 2 study is to assess the feasibility and efficacy of neoadjuvant immunotherapy in patients with previously untreated, surgically-resectable, solid tumor brain metastases.
- Trial name
- NCT04434560
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sarah Sammons, MD
Metastatic Breast Cancer
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
This study will evaluate the efficacy, safety and patient-reported outcomes of trastuzumab emtansine plus atezolizumab compared with trastuzumab emtansine plus placebo in participants with HER2-positive and PD-L1-positive LABC or…
- Trial name
- KATE3 (NCT04740918)
- Testing
- Trastuzumab Emtansine, Atezolizumab
- Where
- 51 sites in United States, Australia and 17 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer
The purpose of this study is to learn more about how a new study agent works inside the body. The study agent is a protein called 64Cu-trastuzumab.
- Trial name
- Cu-64 HER2+ (NCT00605397)
- Testing
- PET Imaging With Cu-64 Labeled Trastuzumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Chemotherapeutic Agent Toxicity
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
RATIONALE: Gathering information over time from laboratory tests, imaging scans, and assessment tests may help doctors learn more about the side effects of chemotherapy and plan the best treatment.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Fatigue
- Trial name
- NCT00755313
- Testing
- trastuzumab, aromatase inhibition therapy, carboplatin
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
This Phase 1 dose-escalation trial is to determine the safety, tolerability and recommended phase 2 dose of talazoparib in combination with belinostat in subjects with Metastatic Breast Cancer, Metastatic Castration Resistant…
- Conditions
- Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma, Metastic or Unresectable Pancreatic Adenocarcinoma
- Trial name
- NCT04703920
- Testing
- Talazoparib, Belinostat
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Michigan Rogel Cancer Center
Neoplasms, Breast
Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
This is an open-label, single-arm, multi-center, Phase II study to determine the activity of vinorelbine plus lapatinib in either first- or second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC).
- Trial name
- NCT00709618
- Testing
- Lapatinib, Vinorelbine
- Where
- 22 sites in United States
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Metastatic Progressive Castration-resistant Prostate Cancer, Metastatic Progressive Breast Cancer
Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method
The primary objective of the preliminary lead-in study is to determine whether circulating tumor cells in patients with metastatic progressive castration-resistant prostate cancer or metastatic progressive breast cancer can be…
- Trial name
- CTC-EMT (NCT02025413)
- Testing
- Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Duke University
Advanced Cancers
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
The goal of this clinical research study is to find the highest tolerable doses of the combinations of lenalidomide and other drugs that can be given to patients with advanced cancer.
- Trial name
- NCT01183663
- Testing
- Lenalidomide, Bevacizumab, Sorafenib
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- M.D. Anderson Cancer Center
HER2-positive Breast Cancer
Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.
The objective of this non-interventional study (NIS) is to evaluate tucatinib (TUKYSA®) combined with trastuzumab and capecitabine in adult patients with locally advanced or metastatic HER2-positive breast cancer who have been…
- Trial name
- TRACE (NCT05253911)
- Testing
- TUKYSA®
- Where
- 2 sites in Austria, Germany
- Volunteers
- 49 people
- Sponsor
- iOMEDICO AG
Triple Negative Breast Cancer
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
The Nanosomal Docetaxel Lipid Suspension (NDLS) consists of uniformly sized micro particles of docetaxel suspended in a lipid based formulation.
- Trial name
- NCT03671044
- Testing
- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Nanosomal Docetaxel Lipid Suspension (100 mg/m2), Taxotere® (100 mg/m2)
- Where
- 4 sites in United States, India
- Volunteers
- 657 people
- Sponsor
- Jina Pharmaceuticals Inc.
Metastatic Breast Cancer
Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer
This is a phase I/II study to determine the safety and gain insight into the immune response of the immunologic agent dHER2+AS15 ASCI when administered in combination with lapatinib.
- Trial name
- NCT00952692
- Testing
- dHER2 + AS15 ASCI, Lapatinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Michael Morse, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.